Opinion: Fighting the Resistance
25 August 2016
Jane Cadzow’s Good Weekend feature quite rightly celebrates the advent of immunotherapies in cancer treatment and the results these are delivering for patients especially, but not only, in melanoma.
However, like a palimpsest there is another story underneath which must be revealed. This feature just touches on it: resistance. If immunotherapies have emerged as the promised land for cancer patients, then resistance is its border crossing. Currently, we have no way of knowing who will successfully make it across the border and why. These ‘wonder drugs’ only work for 70% of patients. The other 30% do not respond at all. Similarly, targeted therapies, which block the action of a particular mutated gene, work initially in 95% of patients but 70% will develop resistance over time.
Nowhere have immunotherapies demonstrated greater success than in treatment of advanced melanoma. Previously, melanoma was the cancer no one wanted to have because the only treatment was surgery and that only worked if diagnosed early. Today through our clinical trials program at Melanoma Institute Australia, we are achieving remarkable results with patients with advanced melanoma which has spread to other organs. Their one-year survival rate in 2011 was 25%. It is now 75%. Their two-year survival rate is over 50%. It used to be less than 15%.
The next frontier in cancer research is unlocking the mystery of resistance and how to overcome it, as well as developing the ability to accurately predict an individual’s response to therapies. The vast array of samples held in our BioSpecimen Bank, the largest in melanoma in the world, are enabling this research. Liquid biopsies are being developed with bloods as early predictors of therapeutic outcome. Tissue donated whilst on therapy is being used to examine both the tumour genome and its micro-environment to discover the drivers of resistance.
Resistance is the story in cancer today, and an even more significant narrative in other tumours than in melanoma. As drugs developed for melanoma are now leading the way, it is our aspiration that in short order it will be melanoma research which surmounts the obstacle of resistance to truly enable precision medicine for cancers: the right therapy for the right person, at the right time and in the right dose, so we really can claim cure.
Carole Renouf
Chief Executive Officer
Melanoma Institute Australia
MIA joins Sydney Health Partners
Sydney Health Partners' goal is to ensure world class research is successfully implemented & scaled-up to benefit patients & wider society.
Congratulations Dr Hansol Lee
Promising young MIA researcher conferred with University of Sydney PhD.
Olympians join forces for melanoma warning
Jana Pittman and Melinda Gainsford-Taylor urge Australians to be sun-safe and check their skin as they join the Game On Mole campaign in support of their much-loved coach
MIA research wins Cancer Institute of NSW 'Wildfire Highly Cited Publication'
Cited an incredible 427 times around the world, showing its vital role in improving outcomes for people with advanced melanoma.
Prof Richard Scolyer receives University of Tasmania Distinguished Alumni Award
Honouring the exceptional impact of his work on communities around the world.
MIA's Co-Medical Directors receive University of Sydney's Vice-Chancellor's Award for Outstanding Research
Awarded for their life-saving discoveries transforming melanoma patient care.
Aussies urged to mark start of summer by checking their skin
National day of action called amidst fears COVID lockdowns have deterred patients from seeking potentially life-saving medical treatment
Prof Georgina Long AO awarded the 2021 Ramaciotti Medal for Excellence in Biomedical Research
Recognising her pioneering work in immunotherapy in melanoma, transforming the care of patients worldwide.
AMC2021 conference wrap-up
Clinicians and researchers from across Australia and beyond united online, bringing the AMC2021 conference theme of Promising Futures to life.
Journalist and news reader Peter Overton our new National Ambassador
Melanoma Institute Australia is proud to announce that the Nine Network’s Peter Overton AM has joined us as a National Ambassador.
MIA researchers feature on prestigious Highly Cited Researchers 2021 List
MIA is proud to announce that five of our researchers have been named on the Clarivate Annual Highly Cited Researchers™ 2021 list.
New research into importance of skin surveillance to save lives from melanoma
New research shows routine skin checks by a health professional, coupled with checking your own skin, are vital in saving lives from melanoma.
Game On Mole - saving lives this summer
With new patient figures indicating people may have deferred skin checks during the pandemic our Game On Mole campaign is more important than ever.
Melanoma March physical events in 2022
We are excited to announce a return to our much-loved physical Melanoma March events in March 2022!
Community Fundraising Wrap Up July-Sept 2021
Read more about the wonderful MIA community fundraising initiatives held recently.
Australian researchers spearhead paradigm shift in melanoma treatment
Drug therapy set to become standard treatment in high-risk early stage patients to stop disease spread
Melanoma Bike Bash 2021: What a ride!
Over two fun, yet challenging, days in September an intrepid group of riders and crew successfully completed the annual Melanoma Bike Bash in WA!
Prof Georgina Long AO awarded inaugural Outstanding Female Researcher Medal from AAHMS
Prof Long AO has been recognised by Australian Academy of Health and Medical Sciences for her transformative work advancing melanoma treatments.
MIA researchers awarded $7.2m in NHMRC grants for health research
Three MIA researchers at University of Sydney received grants to further their important melanoma research.
Amie St Clair Ball in Wagga postponed for a third time
COVID restrictions continue to impact fundraising for melanoma services in Riverina.